Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
ENDOCYTE INC (ECYT) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/07/2018 8-K Quarterly results
Docs: "Endocyte Provides Third Quarter 2018 Financial Results and Operational Update"
07/31/2018 8-K Quarterly results
Docs: "Endocyte Provides Second Quarter 2018 Financial Results and Operational Update -Initiated phase 3 VISION study of 177Lu-PSMA-617 in mCRPC- -Secured commercial supply of no-carrier-added Lutetium-177 through 2035-"
05/09/2018 8-K Quarterly results
Docs: "Endocyte Provides First Quarter 2018 Financial Results and Operational Update – Recently Updated Phase 2 Data on 177Lu-PSMA-617 Published in The Lancet Oncology Favorable to Preliminary Data Presented at 2017 ESMO Congress –"
02/26/2018 8-K Quarterly results
Docs: "Website Information"
11/06/2017 8-K Quarterly results
Docs: "Website Information"
08/08/2017 8-K Quarterly results
Docs: "Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update - Plans to Initiate Clinical Development for CAR T-Cell Program in Osteosarcoma in 2018 –"
05/10/2017 8-K Form 8-K - Current report
03/10/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
05/04/2016 8-K Form 8-K - Current report
03/02/2016 8-K Quarterly results
Docs: "Endocyte Reports Fourth Quarter and Year End 2015 Financial Results and Provides Clinical and Pipeline Update"
11/03/2015 8-K Quarterly results
Docs: "Endocyte, Inc. Statements of Operations For the Three Months Ended September 30, For the Nine Months Ended September 30, 2014 2015 2014 2015 Collaboration revenue $ 3,904 $ 33 $ 70,341 $ 58 Costs and expenses: Research and development 5,675 6,582 37,652 19,923 General and administrative 4,007 3,776 19,476 12,207 Total costs and expenses 9,682 10,358 57,128 32,130 Income from operations 13,213 Interest income, net 161 153 414 490 Other income , net 170 106 Net income $ $ $ 13,540 $ Net income per share: Basic $ $ $ 0.34 $ Diluted $ $ $ 0.33 $ Comprehensive income $ $ $ 13,408 $ Weighted average number of common shares used in net income per share: Basic 41,564,840 41,974,518 39,738,685 41,924,252 Diluted 41,564,840 41,974,518 41,493,711 41,924,252 Endocyte, Inc. Balance Sheets"
08/04/2015 8-K Quarterly results
Docs: "Endocyte Reports Second Quarter 2015 Financial Results and Provides Update on Clinical Progress"
05/07/2015 8-K Quarterly results
Docs: "Endocyte, Inc. Statements of Operations For the Three Months Ended March 31, 2014 2015 Collaboration revenue $ 17,269 $ 12 Costs and expenses: Research and development 12,987 6,617 General and administrative 7,501 4,360 Total costs and expenses 20,488 10,977 Loss from operations Interest income, net 85 152 Other expense, net Net loss $ $ Net loss per share – basic and diluted $ $ Comprehensive loss $ $ Weighted average number of common shares used in net loss per share – basic and diluted 36,193,942 41,857,905 Endocyte, Inc. Balance Sheets"
03/02/2015 8-K Quarterly results
Docs: "Endocyte, Inc. Statements of Operations For the Three Months Ended December 31, For the Twelve Months Ended December 31, 2013 2014 2013 2014 Collaboration revenue $ 17,274 $ 12 $ 64,871 $ 70,353 Costs and expenses: Research and development 13,533 3,998 57,899 41,650 General and administrative 6,704 4,201 25,314 23,677 Total costs and expenses 20,237 8,199 83,213 65,327 Income from operations 5,026 Interest income, net 89 164 464 578 Other expense, net Net income $ $ $ $ 5,459 Net income per share: Basic $ $ $ $ 0.14 Diluted $ $ $ $ 0.13 Comprehensive income $ $ $ $ 5,259 Weighted average number of common shares used in net income per share: Basic 36,146,061 41,736,930 36,036,996 40,242,352 Diluted 36,146,061 41,736,930 36,036,996 41,758,101 Endocyte, Inc. Balance Sheets As of December ..."
11/05/2014 8-K Quarterly results
Docs: "Endocyte Reports Third Quarter Financial Results and Provides Clinical Update"
07/29/2014 8-K Quarterly results
Docs: "Endocyte, Inc. Statements of Operations"
05/02/2014 8-K Quarterly results
Docs: "Endocyte Reports First Quarter Financial Results and Provides Clinical Update",
"Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis"
02/24/2014 8-K Quarterly results
Docs: "Endocyte Reports Fourth Quarter and Year End 2013 Financial Results and Provides Business Update"
11/05/2013 8-K Form 8-K - Current report
08/01/2013 8-K Quarterly results
Docs: "Endocyte, Inc. Statements of Operations"
05/02/2013 8-K Form 8-K - Current report
02/25/2013 8-K Quarterly results
Docs: "Endocyte, Inc. Statements of Operations"
11/01/2012 8-K Form 8-K - Current report
08/02/2012 8-K Form 8-K - Current report
05/10/2012 8-K Form 8-K - Current report
03/13/2012 8-K Form 8-K - Current report
11/10/2011 8-K Form 8-K - Current report
08/11/2011 8-K Form 8-K - Current report
05/05/2011 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy